Genome & Company (314130.KQ) — Stock Score Summary

Genome & Company (314130.KQ) has a MoatMap StockRank of 25/100 based on Quality (32/100), Value (42/100), and Momentum (38/100) factor scores. The current signal is SELL. Genome & Company is a clinical-stage biotechnology company focusing on microbiome therapeutics. It is a consumer of CDMO services rather than a provider, meaning it faces rising manufacturing costs and lacks the cash-generative quality profile of a compounder.

Genome & Company is a South Korean clinical-stage biotechnology company specializing in microbiome-based therapeutics and novel immune checkpoint inhibitors. The company's competitive moat is built on its proprietary GNOCLE platform, which integrates clinical data with microbiome analysis to discover novel drug candidates. Genome & Company operates as an innovative niche player in the emerging global microbiome therapeutics market.

Key Financial Metrics

Price$3.68
Market Cap$146M
Price/Book1.64
Return on Equity-7.1%
Return on Invested Capital-3.2%
Debt/Equity23.79
Gross Margin53.6%
Operating Margin-105.4%
Revenue Growth-9.0%
Free Cash Flow$-1K

Genome & Company operates in the Biotechnology industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is Genome & Company’s (314130.KQ) StockRank?
MoatMap’s StockRank for Genome & Company (314130.KQ) is 25/100, with a Sell signal. It is a composite of Quality (32), Value (42), and Momentum (38) factor ranks across MoatMap’s 19,000+ stock universe.
Does Genome & Company have an economic moat?
Genome & Company (314130.KQ) has a Quality factor score of 32/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Genome & Company a buy, hold, or sell?
MoatMap’s current signal for Genome & Company (314130.KQ) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Genome & Company in?
Genome & Company (314130.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).
Browse all ranked stocks314130.KQ deep dive reportAI ChampionsHow we score stocksSense-check another stock